RhumbLine Advisers’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-976
| Closed | -$1.09K | – | 4156 |
|
|
2025
Q2 | $1.09K | Sell |
976
-20,355
| -95% | -$24.9K | ﹤0.01% | 4030 |
|
|
2025
Q1 | $24.5K | Sell |
21,331
-1,287
| -6% | -$2.39K | ﹤0.01% | 3711 |
|
|
2024
Q4 | $138K | Buy |
22,618
+2,332
| +11% | +$27.7K | ﹤0.01% | 3368 |
|
|
2024
Q3 | $336K | Sell |
20,286
-2,440
| -11% | -$26.7K | ﹤0.01% | 2966 |
|
|
2024
Q2 | $156K | Buy |
22,726
+2,635
| +13% | +$22.5K | ﹤0.01% | 3365 |
|
|
2024
Q1 | $194K | Buy |
20,091
+887
| +5% | +$10.3K | ﹤0.01% | 3200 |
|
|
2023
Q4 | $160K | Buy |
19,204
+508
| +3% | +$2.95K | ﹤0.01% | 3286 |
|
|
2023
Q3 | $156K | Sell |
18,696
-2,154
| -10% | -$18.3K | ﹤0.01% | 3286 |
|
|
2023
Q2 | $192K | Buy |
20,850
+5,915
| +40% | +$66.3K | ﹤0.01% | 3254 |
|
|
2023
Q1 | $205K | Buy |
14,935
+204
| +1% | +$4.22K | ﹤0.01% | 2734 |
|
|
2022
Q4 | $251K | Buy |
14,731
+491
| +3% | +$9.82K | ﹤0.01% | 2729 |
|
|
2022
Q3 | $324K | Buy |
14,240
+1,357
| +11% | +$27.4K | ﹤0.01% | 2694 |
|
|
2022
Q2 | $232K | Buy |
12,883
+3,661
| +40% | +$65.3K | ﹤0.01% | 2876 |
|
|
2022
Q1 | $247K | Buy |
9,222
+1,308
| +17% | +$24.4K | ﹤0.01% | 2701 |
|
|
2021
Q4 | $232K | Sell |
7,914
-142
| -2% | -$7.06K | ﹤0.01% | 2791 |
|
|
2021
Q3 | $530K | Buy |
8,056
+361
| +5% | +$27.6K | ﹤0.01% | 2513 |
|
|
2021
Q2 | $640K | Buy |
7,695
+40
| +0.5% | +$2.96K | ﹤0.01% | 2443 |
|
|
2021
Q1 | $587K | Sell |
7,655
-316
| -4% | -$28.8K | ﹤0.01% | 2410 |
|
|
2020
Q4 | $704K | Buy |
7,971
+420
| +6% | +$29.5K | ﹤0.01% | 2291 |
|
|
2020
Q3 | $557K | Sell |
7,551
-1,260
| -14% | -$74.6K | ﹤0.01% | 2239 |
|
|
2020
Q2 | $643K | Buy |
8,811
+3,881
| +79% | +$236K | ﹤0.01% | 2233 |
|
|
2020
Q1 | $277K | Buy |
+4,930
| New | +$216K | ﹤0.01% | 2444 |
|
Other funds holding IGMS
RhumbLine Advisers's IGMS Position: Q3 2025 in Review
RhumbLine Advisers sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 976 shares — an estimated $1.09K sold.
RhumbLine Advisers first reported a position in IGMS in Q1 2020 and held it in 22 quarters. The position peaked at $704K in Q4 2020. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- RhumbLine Advisers reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- RhumbLine Advisers sold 976 IGM Biosciences shares in Q3 2025, an estimated $1.09K.
- RhumbLine Advisers first reported a position in IGM Biosciences in Q1 2020 and held it in 22 quarters.
- RhumbLine Advisers's IGM Biosciences position peaked at $704K in Q4 2020.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.